WellPrept Patient Education · Cancer Series

Understanding Upper Tract Urothelial Cancer

A guide for adults with cancer in the lining of the renal pelvis or ureter. It is the same cell type as bladder cancer, growing in a different place, and that is what changes the surgery and the follow-up.

Version 1.0 · May 2026 Medically reviewed · Next review May 2027

Welcome

You have been told you have cancer in the lining of the kidney's collecting system or the tube that drains it. The medical name is upper tract urothelial carcinoma, or UTUC for short. Most patients have never heard of it before their diagnosis, even those who have a relative who had bladder cancer. The cells under the microscope look almost identical to bladder cancer cells, but the location of the tumor is what reshapes the operation, the chemotherapy timing, and the years of follow-up that come after.

This guide walks through what UTUC is, how your team sorts it into low risk or high risk, the choice between saving the kidney and taking it out, what chemotherapy can add, and why bladder checks stay part of your life going forward. It works with the Cancer Basics guide for shared words like stage, grade, biopsy, and surveillance, and with the Bladder Cancer (Non-Muscle Invasive) guide for the underlying cell type and the bladder scope (cystoscopy).

How to use this guide. Read it once at your own pace, highlight what fits your situation, and skip what doesn't apply. Bring the questions in Chapter 14 to your next visit. The chapters are short and self-contained so you can come back to any one when a question comes up between visits.

Chapter 01

What UTUC is

UTUC starts in the lining of the renal pelvis or the ureter. This chapter covers the anatomy and how UTUC relates to bladder cancer.

A short anatomy refresher

Your kidneys filter blood and make urine. Inside each kidney, urine first collects in a funnel-shaped space called the renal pelvis. From there, it travels down a thin muscular tube called the ureter, about 10 to 12 inches long, into the bladder. The inside of the renal pelvis, the ureter, and the bladder is all lined with the same kind of tissue. Doctors call this lining the urothelium.

Upper tract urothelial carcinoma is cancer that starts in the urothelium of the renal pelvis or the ureter. About 6 in 10 of these cancers start in the renal pelvis, and about 4 in 10 in the ureter.

The bladder cancer connection

Most urothelial cancer in this country starts in the bladder. Bladder cancer is far more common than UTUC. UTUC makes up about 5 to 10 out of every 100 urothelial cancers. The cells look very similar under the microscope. Many of the same words you may have heard about bladder cancer come up here too: papillary, low-grade, high-grade, recurrence, surveillance.

The big differences are about anatomy. Because the wall of the renal pelvis and ureter is thinner than the bladder wall, a tumor can invade more quickly. The kidney sits right behind it, so removing the cancer can mean removing the kidney. Your bladder still has the same lining after upper tract surgery, which is why bladder surveillance becomes part of your life going forward.

Who gets UTUC

  • The average age at diagnosis is in the early 70s. UTUC is uncommon before age 40, unless an inherited condition like Lynch syndrome is in play.
  • Men are about twice as likely as women to develop it.
  • About 17 out of 100 people with new UTUC have a bladder tumor found at the same time. More will develop one later. Your team will scope your bladder as part of the workup.
  • About 8 to 13 out of 100 people develop an upper tract tumor on the opposite side at some point.
!
A word you will hear: stage

Like other cancers, UTUC has a stage that describes how deep the tumor has grown and whether it has reached lymph nodes or other organs. The walls of the renal pelvis and ureter are thinner than the bladder, so even an early-stage tumor needs to be taken seriously. Up to half of UTUC is already invading the muscle layer by the time it is found.

Chapter 02

Risk factors and causes

UTUC shares most of its causes with bladder cancer. A few are specific enough to UTUC that they deserve their own mention.

Smoking is the big one

About half of UTUC cases trace back to tobacco. The carcinogens in cigarette smoke leave the body in the urine, and they bathe the lining of the renal pelvis, the ureter, and the bladder on the way out. People who have smoked carry roughly three times the risk of people who never smoked. If you still smoke, quitting matters for the rest of your kidney and bladder lining, for your heart, and for how you tolerate treatment. Chapter 13 lists what helps.

Work and chemical exposures

Some jobs raise UTUC risk. The chemicals involved are called aromatic amines. They show up in:

  • Chemical and dye manufacturing
  • Rubber and plastics
  • Leather and tanning
  • Painting and printing
  • Aluminum production
  • Some textile work

The exposure often dates back 20 or 30 years before the cancer shows up. If your work history includes any of the above, let your team know.

Aristolochic acid

This is a plant-based chemical that damages the kidneys and is one of the strongest known causes of UTUC.

  • In some rural Balkan villages, a plant got into the local wheat for many years. Whole families got kidney disease and a high rate of UTUC, often on both sides.
  • In the 1990s, weight-loss herbs sold in many places turned out to have it. UTUC cases followed. It can still show up in unchecked supplements today.

If you take any herbal product, especially anything sold for "kidney support" or "weight loss," ask your team or your pharmacist to look at the list. Plants in the Aristolochia family are the ones to avoid.

Other things on the list

  • Long-term kidney stones or long-term infection in one kidney
  • Past pelvic radiation
  • Past use of a chemo drug called cyclophosphamide
  • Arsenic in drinking water
  • A past bladder cancer. This is why your bladder cancer follow-up may have included some kidney scans.
  • A gene change you can be born with called Lynch syndrome. It gets its own chapter (Chapter 4).

What does not cause it

Patients ask about this a lot. A few common worries have not been shown to cause UTUC. The list includes artificial sweeteners and Tylenol at usual doses. It also includes sexual activity and the common bladder infections that healthy adults get.

Chapter 03

How UTUC is found and worked up

The path to a UTUC diagnosis usually goes through a scan and then a thin scope passed up into the kidney. Both steps matter, because each one tells your team something the other cannot.

The most common reason people come in

About 7 or 8 in 10 people with UTUC first notice visible blood in their urine. It can look bright red, pink, or tea-colored, and it often comes and goes. A smaller group has blood that only shows up on a lab test. Some patients have flank pain instead, a dull ache or pressure on one side of the back. And a smaller group is found by accident, when a CT scan ordered for something unrelated picks up a mass.

The standard workup

  • Urine tests. A simple urinalysis and a urine culture to rule out infection. A test called urine cytology looks for cancer cells in the urine. It is better at picking up high-grade tumors than low-grade ones.
  • CT urogram (CTU). The main imaging study. A CT scan with contrast dye given at the right time to outline the kidneys, the collecting systems, the ureters, and the bladder. If you cannot get contrast for any reason, an MR urogram is the back-up.
  • Cystoscopy. Your team will scope your bladder in the office as part of the workup. About 17 in 100 people with new UTUC have a bladder tumor at the same time, and the plan changes if one is there.
  • Ureteroscopy with biopsy. A thin flexible scope is passed up through the urethra, through the bladder, and up the ureter into the renal pelvis. This is done under anesthesia. Your urologist looks at the tumor, takes a small sample, and often collects urine from that side directly. This is the test that confirms the diagnosis and gives the grade.

Why both the scan and the scope

The CT scan can show your team where the tumor is and how big it looks. It cannot tell them the grade. The scope lets your team see the tumor with their own eyes and take tissue. The grade and the look of the tumor together drive the next decision, which is whether your case is low risk or high risk (Chapter 5). For a small number of patients with a clearly invasive tumor and a normal kidney on the other side, your team may go straight to surgery without a separate scope.

i
Ask for a copy of your pathology report

Once the biopsy is back, ask for a copy. The two words that drive the most decisions are the grade (low or high) and the type. Bring the report to your next visit. Mark anything you do not understand. Your team will go through it with you.

Chapter 04

Lynch syndrome and your family

UTUC is one of the cancers that can run in families because of an inherited gene change. A fairly simple test can change your treatment plan. It can also change the screening plan for your siblings, children, and parents.

What Lynch syndrome is

Lynch syndrome is an inherited condition you're born with. It comes from a change in one of a small set of DNA repair genes. Those genes normally fix the tiny copying errors that happen each time a cell divides. When they don't work well, the errors build up over the years and some turn into cancer. People with Lynch syndrome carry a higher lifetime risk of colon cancer, uterine cancer, and urinary tract cancers (UTUC in particular). The risk is also higher for a handful of less common ones, including ovary, stomach, small bowel, and certain brain and skin cancers.

Why this matters in UTUC

UTUC is the urinary cancer most tied to Lynch syndrome. About 1 to 3 out of 100 people with UTUC have it. The number is higher (up to 5 to 9 out of 100) for people diagnosed under age 65, or for people with a family pattern of these cancers. People with Lynch tend to get UTUC younger (late 50s on average) and are more likely to have tumors on both sides.

Who should be tested

Big urology groups say to ask for gene testing if any of these are true:

  • You got UTUC before age 65
  • You have had a Lynch-linked cancer before. These are colon, uterus, ovary, stomach, small bowel, brain, or some skin cancers.
  • A parent, sibling, or child got a Lynch-linked cancer before age 50
  • Two or more close family members have had Lynch-linked cancers at any age

What testing looks like

Testing happens in two steps.

  • Tumor testing. The lab runs extra stains on your tumor sample. They check if the repair genes worked. This is called MMR or MSI testing.
  • Germline testing. If the tumor test points that way, a blood or spit sample is sent to look at the genes in your body.

What a positive test changes

  • For you. Routine colon scopes, GYN exams for women, and other screens go on your schedule for life.
  • For your family. Parents, siblings, and kids can choose to be tested. Those who carry the same change can start their own screens early.
  • For your care. If your UTUC ever spreads, certain immune drugs work well in this group.
+
Genetic counseling is its own visit

Most cancer centers have a genetic counselor on staff. They walk through what testing covers, what it does not, and what the results would mean for you and your family. A federal law called GINA blocks health insurance and employers from using your genetic test results against you. It does not cover life, disability, or long-term care insurance. A counselor can walk through this before you decide.

Chapter 05

Low risk vs high risk

After the biopsy and the imaging are back, your team sorts UTUC into one of two risk groups. The risk group drives the central decision: try to save the kidney, or take it out.

How the sorting works

Doctors use a checklist of features from the scan, the scope, the biopsy, and the urine cytology. A tumor needs to meet all of the low-risk features to be called low risk. A tumor with even one high-risk feature gets called high risk. Major guidelines from European and American urology societies agree on this approach.

Low risk
All of these are true:
  • Biopsy is low-grade
  • Tumor looks papillary (like a small frond) on imaging or scope
  • One tumor, not several
  • Tumor is under about 2 cm
  • Scan does not suggest the tumor is invading deeper tissue
  • No blockage of the kidney from the tumor
  • Urine cytology is not high-grade
High risk
Any one of these is true:
  • Biopsy or urine cytology is high-grade
  • Tumor looks flat or sessile, not papillary
  • More than one tumor along the upper tract
  • Tumor is 2 cm or larger
  • Scan shows the tumor is blocking the kidney
  • Scan suggests the tumor is invading nearby tissue
  • Unusual cell type on pathology
  • You have a history of high-grade bladder cancer

What the risk group changes

A small low-grade tumor in the lower ureter often does well with a kidney-saving surgery. It may even respond to a gel form of chemo (see Chapter 7). A high-grade tumor that blocks the kidney is a much bigger deal. It often means taking out the kidney and the full ureter on that side. Chemo on top may be needed.

Why staging UTUC is harder than staging bladder cancer

Biopsies in the ureter and renal pelvis are small, and the wall is thin. Scans cannot always tell if a tumor is shallow or starting to spread. Your team puts together scan results, the biopsy, the cytology, and good judgment. When the picture is mixed, they tend to lean toward more care. If your case sits in that mixed middle, ask if a second opinion at a high-volume center makes sense. Many people get one at this point.

Chapter 06

Saving the kidney: low-risk options

For low-risk UTUC, the goal is to treat the tumor and keep the kidney working. Three options sit on the table, and they can be used together over time.

Ureteroscopic ablation

A thin flexible scope is passed up to the tumor, same as during the biopsy. Your urologist uses a small laser fiber through the scope to destroy the tumor in place. This is often a same-day or short-stay procedure. The tradeoff is that you usually come back for a repeat scope at about 3 months to check the area and to treat anything left or anything new. This staged approach is normal and is part of how kidney-sparing care works.

Segmental ureterectomy

If the tumor is in the lower part of the ureter and is too large or in an awkward spot for a scope, the surgeon can remove that segment of the ureter and connect the healthy parts back together. Sometimes a portion of the bladder is used to bridge a gap, or a longer piece of bowel is brought up if a long stretch needs to be replaced. The kidney stays.

Percutaneous resection (less common)

For a few tumors deep in the renal pelvis that the scope cannot reach well from below, your surgeon may go in through a small cut in the back. They treat the tumor from above, through a working tube. This is saved for some low-grade tumors. There is a small chance of cancer cells settling along the path, so it is used with care.

What kidney-sparing means in practice

  • Many visits and many scopes over a year or more
  • The kidney stays and keeps working
  • The cancer can come back in the same spot or in a new spot on the same side
  • Sometimes a later biopsy comes back high-grade, or the tumor grows. Then your team will lean toward removing the kidney.

Some people have only one working kidney. The other may have been taken out long ago, may never have formed, or may no longer work. For those people, kidney-saving care is a top goal even when the cancer is high-risk. Your team will push harder on repeat scopes and use longer staged care. The gel chemo in the next chapter is often part of that plan.

i
Map out the first 12 months

Kidney-saving care runs over a year or more. It uses repeat scopes every few months to check the same spot and treat anything new that pops up. A first plan often runs to four visits or more. Ask your team to map out the next 12 months on a calendar at the start, so the schedule is clear before you commit.

Chapter 07

Mitomycin gel (Jelmyto)

A newer option, OK'd in 2020, lets your team put chemo right into the renal pelvis as a gel. It is the first drug ever made just for low-grade UTUC. (Full name: Mitomycin reverse-thermal gel, or Jelmyto.)

What it is

Jelmyto, sometimes written as mitomycin pyelocalyceal solution, is a familiar chemotherapy drug (mitomycin C) mixed into a heat-sensitive liquid carrier. The temperature behavior is what makes it work. Kept cold, the solution is a thin liquid that flows easily through a small catheter. Once it warms to body temperature inside the renal pelvis, it turns into a soft gel. That gel sits against the lining for several hours, then melts back into liquid and drains out with urine.

How it is given

The drug is placed into the renal pelvis through a thin catheter that runs from the bladder up the ureter, or sometimes through a small tube that goes through the back into the kidney. You receive a series of six weekly treatments. Your team checks the response at about 3 months. People who have a complete response can go onto monthly maintenance treatments to keep the area clean.

What the main study showed

59%
had a complete response at 3 months in the main trial
84%
of those responders were still clear at 12 months on monthly maintenance
44%
developed narrowing of the ureter in the trial

Your numbers may differ from the trial. Newer real-world reports from clinics that use Jelmyto regularly are still being added to the picture.

Where it fits

  • Biopsy-proven low-grade UTUC, most of all when it sits in the renal pelvis where the scope cannot reach every nook
  • People with one working kidney, where keeping the kidney is the top goal
  • Small low-grade tumors that came back after a scope treatment

Side effects to know about

The big one is narrowing of the ureter. This can block urine flow. It may need a stent or another procedure to open up. Other common side effects in the trial were flank pain, blood in the urine, feeling tired, and bladder infections. Call your team the same day if you have new flank pain, fever, or a clear drop in how much you are urinating on the treated side.

+
Ask whether Jelmyto fits you

Jelmyto is not used for every UTUC. It is meant for low-grade disease, and not every clinic offers it. If your tumor is low-grade and your team has not brought it up, ask whether you are a fit. You can also ask about a referral to a center that does offer it.

Chapter 08

Removing the kidney and ureter

Most people regain a full life after radical nephroureterectomy, with a lost kidney and years of surveillance to manage.

What the operation is

For high-risk UTUC, the standard operation is called radical nephroureterectomy, often shortened to RNU. It removes three things on the affected side: the whole kidney, the entire ureter from the kidney down to the bladder, and a small cuff of bladder at the spot where the ureter joins it. The bladder cuff is essential. Leaving a stump of ureter behind would leave a high chance of new tumor at that spot.

The kidney loss conversation

You will lose the kidney on the cancer side, and if your other kidney is healthy, you can expect to do well on one. Your overall kidney function typically drops by about 25 to 30 percent after surgery, which sounds like a lot but is generally well tolerated. That drop can also take cisplatin chemotherapy off the table afterward (more on that in the next chapter). The dialysis question almost never comes up after a standard RNU in someone whose other kidney was already working well. It enters the picture when the other kidney was already compromised going in.

The picture changes if your other kidney was already weak. It also changes if the cancer side is your only working kidney. Kidney-sparing surgery then becomes a serious option, even with high-risk disease. This is a good moment to ask for a second opinion at a high-volume center.

How the surgery is done

RNU is done three ways. Open uses one larger cut. Laparoscopic uses many small cuts with a camera. Robotic uses small cuts guided by a robot. All three are good surgeries in skilled hands. At many high-volume centers the robotic way is now the most common. The cancer results are about the same when done by surgeons who do this often.

Your surgeon will also take out the nearby lymph nodes if your tumor is high-risk. This step is called lymph node dissection. The lymph nodes tell the lab more about how the cancer is behaving. They also help guide the chemo choice.

What recovery looks like

  • Hospital stay is usually about 2 to 5 days
  • A urinary catheter stays in for several days to a week so the bladder cuff site can heal
  • Most people are back to light activity in 2 to 4 weeks
  • Full return to baseline often takes 6 to 12 weeks
  • The remaining kidney gets a little bigger and takes on more of the work over the following weeks and months

A single dose of mitomycin into the bladder, after surgery

Within two weeks of RNU, your team gives a single dose of mitomycin chemotherapy into the bladder through a catheter. A UK trial called ODMIT-C showed this single dose cuts the chance of a bladder tumor in the year after surgery from about 32 in 100 to about 17 in 100. It is now standard care after RNU when there is no reason not to give it. Mitomycin is the most studied. Gemcitabine and a related drug are reasonable alternatives if a center stocks them.

Chapter 09

Chemotherapy before or after surgery

For high-risk UTUC, chemo on top of surgery helps with the odds of staying cancer-free. The newer question is when to give it. Before the surgery, or after.

Why chemotherapy is on the table

Urothelial cancer is one of the cancer types that responds well to a family of chemotherapy drugs called platinum-based. The two main ones are cisplatin and carboplatin. They are given by IV, usually paired with another drug called gemcitabine, over several cycles spaced a few weeks apart. Hair changes, tiredness, low blood counts, nausea, and tingling in the fingers and toes are common. Your medical oncologist runs this part of your care.

Adjuvant chemotherapy: after surgery

A UK trial called POUT tested adding four cycles of chemotherapy after RNU in patients whose tumors had invaded the muscle layer or reached lymph nodes. The benefit was large enough that it changed practice almost overnight.

71%
3-year disease-free with chemotherapy after RNU
46%
3-year disease-free with surveillance alone
25
percentage points of benefit, in absolute terms

Sometimes the tumor has grown into muscle or has reached lymph nodes. If you are fit enough for it, chemo after RNU is the standard plan.

Neoadjuvant chemotherapy: before surgery

The catch with giving chemo after surgery is that the kidney is already gone by the time treatment starts. Cisplatin, the strongest platinum drug, needs a certain level of kidney function to be safe. Roughly 1 in 3 patients who would have qualified for cisplatin before RNU no longer qualify after it. Giving chemo up front avoids that problem. It can also shrink the tumor before the operation.

As of 2026, both sequences are reasonable. Many high-volume centers now lean toward chemotherapy first when imaging suggests muscle-invasive disease and kidney function is good, though the phase-3 evidence for upfront chemo is still being built out. Practice varies a lot from center to center, so ask your team where they land on this question and what's driving their answer.

What recently changed

An immune drug called pembrolizumab, given for a year after RNU, became an option for some patients with high-risk muscle-invasive disease. The use of this drug after RNU is newer than the POUT data. Your team will know if your tumor fits.

i
Questions for the cancer doctor

You will likely meet a cancer doctor before or after surgery to talk about chemo. Bring questions. The two big ones are: "Am I a fit for chemo before surgery?" and "If I have surgery first, what will my kidney work need to look like for cisplatin to still be an option?" The answers set the calendar.

Chapter 10

Kidney function and the path ahead

Losing a kidney changes what your body can handle day to day and what your treatment choices look like. Ask for a full conversation about it in clinic.

How much kidney function you lose

The standard high-risk operation removes an entire kidney. That is roughly a quarter to a third of your filtering capacity. Patients whose remaining kidney is healthy tend to adjust without much trouble. For others, the remaining kidney is already weak. The cause may be diabetes, longstanding high blood pressure, vascular disease, or past damage from aristolochic acid. These patients can drop into chronic kidney disease that shows up in daily life.

The number your team will track is your eGFR (estimated glomerular filtration rate), an estimate of how well your kidneys filter. Cisplatin chemotherapy generally needs kidney function above an eGFR of about 60. Below that, most oncologists shift to other options. Some teams will offer split-dose cisplatin or carboplatin at slightly lower eGFR values; the exact cutoff varies by center. After RNU, plenty of patients drop below that line, which is part of why the chemo timing question (Chapter 9) matters so much.

Who should think about kidney-sparing surgery even with high-risk disease

  • People with one working kidney already
  • People who go into surgery with a lot of chronic kidney disease
  • People whose other kidney has its own problem. This can be a known mass, a long-standing block, or its own past surgery.

For these patients, your team may push harder with scope-based treatment over staged visits. They may do segmental ureterectomy when the tumor spot allows. They may use Jelmyto for low-grade disease in the renal pelvis. In some cases, they may use treatment through a small flank cut. None of these is risk-free. Each trades a higher chance of cancer coming back in the same kidney for keeping that kidney working.

The tradeoff in practice

Keeping a kidney that brings a much higher chance of the cancer returning in a worse form isn't a trade most people would take. Neither is surgery that puts you on dialysis. The hard cases sit in the middle. There the cancer risk from kidney-sparing is meaningful but not overwhelming, and the dialysis risk from RNU is possible but not certain. For those patients, a second opinion at a center that sees a high volume of UTUC is a reasonable next step, even if it means travel.

Living with one kidney

  • Keep blood pressure in check. Untreated high blood pressure is the fastest way to wear out a kidney.
  • If you have diabetes, keep it in check as best you can.
  • Stay hydrated.
  • Talk with your primary care doctor before you start any pain pill from the store. NSAIDs like ibuprofen and naproxen can lower kidney work. Tylenol at usual doses is often safer.
  • Quit smoking if you have not.
  • Get a basic blood test of your kidney work at least once a year.
Chapter 11

Surveillance: cystoscopy and scans

After UTUC treatment, follow-up keeps going. Bladder recurrence is common, and recurrence in the opposite upper tract happens too. Surveillance is how both get caught early.

Why bladder surveillance goes on for years

The same urothelial lining that grew your upper tract cancer also lines your bladder. Studies show that about 30 to 50 out of every 100 people who had UTUC get a bladder tumor at some point after. Most show up in the first 2 or 3 years. The single dose of mitomycin given at the end of surgery (Chapter 8) lowers that number. It does not bring it to zero.

What surveillance looks like

The exact plan varies by center and by how high the first risk was. A common schedule after RNU:

  • Cystoscopy (a quick office scope of the bladder) at 3 months. Then every 3 to 6 months for the first 2 years. Then every 6 to 12 months for years 3 to 5. Then yearly for many people. For most patients this goes on for life.
  • Urine cytology at the same times, especially if the first cancer was high-grade.
  • CT scan of the belly and pelvis at set times. This watches the other upper tract and looks for any spread. Often every 6 to 12 months in the first 2 to 3 years for high-risk disease, then yearly.
  • Blood work to track the remaining kidney's work.

For people who had kidney-sparing treatment

If you kept the kidney, the same upper tract still has the same lining that grew a tumor. Repeat ureteroscopy is part of follow-up, often at 3 months, 6 months, and at intervals after that for as long as your team feels is right. Cystoscopy on the bladder continues too. The schedule is more involved than after RNU.

The surveillance load is heavy

Office cystoscopies are uncomfortable for most people, scans cost time and money, and the week before each test reliably brings on what patients call scanxiety. A few practical things take the edge off. Booking the scope or scan early in the week shortens the wait. Asking for the result on the same day or within 48 hours, rather than at the next appointment, keeps a hard number from sitting unread. If the anxiety is interfering with sleep or work, a few sessions with a therapist who works with cancer patients help. Catching a recurrence while it is small and treatable is what the scopes are for.

+
Build the calendar early

Before you leave the office after your treatment plan is set, ask: "What does my next 12 to 24 months of follow-up look like?" Put each date on your phone or your wall calendar.

Chapter 12

If the cancer has spread

Some patients are diagnosed with UTUC that has already spread to lymph nodes or other organs. Others develop spread later. The drugs for metastatic urothelial cancer have changed fast in recent years, and this chapter covers the main categories.

What "metastatic" means here

Metastatic UTUC means the cancer has reached spots beyond the kidney and ureter, most often distant lymph nodes, lungs, liver, or bone. Treatment is given by IV or by mouth and travels through the bloodstream. The goal is to control the cancer, give you more time, and protect your quality of life. The same systemic drugs used for metastatic bladder cancer are used for metastatic UTUC.

First-line options today

  • Enfortumab vedotin plus pembrolizumab (often written EV plus Pembro). It was OK'd in late 2023 as a first-line drug for most people with metastatic urothelial cancer. A study called EV-302 showed people on this combo lived almost twice as long on average as people on older platinum chemo alone.
  • Platinum chemo (cisplatin or carboplatin paired with gemcitabine) is still an option. It is especially useful for people who do not fit the newer combo.
  • Avelumab, an immune drug, can be used as upkeep after platinum chemo in people whose cancer did not grow.

For selected tumor types

  • Erdafitinib, a pill that blocks a signal called FGFR, is an option when the tumor has a set FGFR change. FGFR changes show up more often in UTUC than in bladder urothelial cancer. So testing for it makes sense.
  • Pembrolizumab and other immune drugs are used in later lines. They work well when the tumor is MSI-high or has a Lynch-linked pattern.

Other things to know

New drugs for metastatic UTUC arrive quickly, so what is true today may change within a year. Ask for a referral to a high-volume cancer center for drug choices and trial access at any point.

Palliative care belongs in the picture early, at the same time as active treatment. It's a team that focuses on symptoms (pain, nausea, fatigue, sleep, mood, family conversations) while your oncologist runs the cancer drugs. Patients sometimes turn down the referral because they read it as a signal of giving up. Multiple large studies across different cancers have shown that patients who get palliative care alongside treatment feel better and, in some studies, live longer. If your team hasn't offered it, ask.

Hospice is a separate service. Hospice provides comfort care for patients who are no longer pursuing treatment aimed at cancer control. It doesn't mean death is days or weeks away, and a fair number of patients on hospice live longer and more comfortably than they would have on continued treatment.

Chapter 13

What you can do on your own

A lot of UTUC is out of your hands. The list below is what the evidence supports patients doing, in roughly the order these come up in clinic.

Quit smoking and stay quit

Smoking is the biggest driver of UTUC, and it helps push recurrences along. Quitting is the single most useful thing in your control. Several tools work, and they work best together: nicotine replacement (patches, gum, lozenges), prescription pills like varenicline and bupropion, counseling, and free state quit lines. Ask your team for a referral and a prescription. Most patients who quit for good have several failed tries behind them, so an earlier failed quit does not mean you can't do it.

Show up for every surveillance visit

Cystoscopy, urine cytology, and scans on schedule are what catch a new bladder tumor or a tumor on the other side early, while it is still small. Keeping every scope appointment is one of the strongest ways to catch a recurrence at a treatable stage. Putting each date on the calendar before you leave the office makes that easier.

Protect the kidneys you have

  • Get your blood pressure under good control
  • If you have diabetes, work with your team on the numbers
  • Stay hydrated
  • Skip regular use of NSAIDs like ibuprofen and naproxen unless your team OKs it
  • Get a yearly basic kidney lab test even when you feel fine

Be careful with herbal supplements

Plants in the Aristolochia family cause UTUC. If you take any herbal product, especially anything sold for "kidney support," weight loss, or "detox," bring the bottle to your visit. Let your team or pharmacist look at the list.

Bring a full medication and supplement list

Every visit. Include store-bought items and vitamins. Some mix poorly with chemo or the gel treatment. Some matter for kidney work.

Know your family history

If you have any of the family patterns from Chapter 4 (Lynch syndrome), ask about a gene counselor referral. A "yes" result changes your screens, your family's screens, and your future drug choices.

Pick the right place to be treated

UTUC is rare, and many local urologists see only a few cases per year. High-volume centers see more, and they tend to have steady ureteroscopy and robotic skill, regular tumor boards, and access to trials. A second opinion or shared care with a high-volume center makes sense at any point. It is most useful before a big choice, like kidney-saving vs RNU, the chemo timing call, or drug care for spread.

The bladder cancer community

The Bladder Cancer Advocacy Network (BCAN) is the main patient group. It has tools for UTUC next to its larger bladder cancer programs. The link is in the sources list.

Chapter 14

Questions and words to know

Bring this page to your next visit. A written list is easier than remembering the questions in the exam room.

About my cancer

  • Where exactly is my tumor, and is it low risk or high risk?
  • What grade did the biopsy show?
  • Has my case been reviewed at a tumor board?

About the plan

  • Am I a fit for kidney-saving care? Why or why not?
  • Am I a fit for Jelmyto?
  • If I need RNU, what will my kidney work look like after?
  • Should I see a cancer doctor before surgery, or after?
  • Is chemo before surgery a fit for me?

About family and surveillance

  • Should I see a gene counselor for Lynch syndrome testing?
  • What does my check-up schedule look like for the next 1 to 2 years?
  • Who do I call for scope results and scan results?

About the road ahead

  • Is a second opinion at a high-volume center a good idea here?
  • Are there trials open for my case right now?
  • What is your best estimate of how my case will go?

Words to know

UTUC
Upper tract urothelial carcinoma. Cancer of the lining of the renal pelvis or ureter.
Renal pelvis
The funnel-shaped space inside the kidney where urine first collects.
Ureter
The thin muscular tube that carries urine from the kidney to the bladder.
Urothelium
The lining of the renal pelvis, ureter, bladder, and part of the urethra.
Hematuria
Blood in the urine. Gross hematuria is visible. Microscopic is found on a lab test.
Hydronephrosis
Swelling of the kidney from urine that cannot drain.
CT urogram
A multi-step CT scan with contrast that shows the kidneys, collecting systems, ureters, and bladder.
Ureteroscopy
Passing a thin scope up through the urethra and bladder into the ureter and kidney.
Cystoscopy
A scope of the bladder through the urethra. Done in the office.
Cytology
Looking at urine for cancer cells under the microscope.
Grade
How aggressive the cancer cells look. Low-grade or high-grade.
Lynch syndrome
An inherited condition that raises risk of colon, uterine, urothelial, and other cancers.
MMR / MSI
Lab tests on the tumor that suggest Lynch syndrome.
Aristolochic acid
A plant chemical that causes kidney damage and UTUC. Found in some herbal supplements.
Kidney-sparing surgery
Treating the tumor while keeping the kidney.
Ureteroscopic ablation
Using a laser through a scope to destroy the tumor in place.
Segmental ureterectomy
Removing a section of the ureter with the tumor and reconnecting the healthy parts.
Jelmyto
A gel form of the chemotherapy drug mitomycin C. Put into the renal pelvis to treat low-grade UTUC.
RNU
Radical nephroureterectomy. Surgery to remove the whole kidney, the entire ureter, and a small cuff of bladder.
Bladder cuff
A small piece of bladder removed during RNU at the spot where the ureter joined the bladder.
Lymph node dissection
Removing nearby lymph nodes during the cancer operation to check them and to improve staging.
POUT trial
The UK study that showed chemotherapy after RNU improves disease-free survival.
ODMIT-C trial
The UK study that showed a single dose of mitomycin into the bladder after RNU lowers bladder recurrence.
Cisplatin / carboplatin
Platinum-based chemotherapy drugs used in urothelial cancer.
eGFR
An estimate of how well the kidneys filter. A measure of kidney function.
Adjuvant
Treatment given after the main surgery.
Neoadjuvant
Treatment given before the main surgery.
EV + Pembro
Enfortumab vedotin plus pembrolizumab. A first-line combination for metastatic urothelial cancer.
FGFR inhibitor
A pill that targets a specific change in some urothelial tumors. Erdafitinib is the main one.
Recurrence
The cancer comes back after a clear period.
Contralateral
On the opposite side.
Palliative care
Care for symptoms and quality of life alongside treatment. Not hospice.
Hospice
Comfort care when treatment for cancer control is no longer being pursued.
Sources

Sources and further reading

This guide draws on current society guidelines and the major trials behind today's standard of care. The list below points to where you can read more.

  1. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma. uroweb.org
  2. NCCN Kidney Cancer and Bladder Cancer Patient Guidelines. nccn.org/patients
  3. POUT trial (adjuvant chemotherapy after RNU), Lancet 2020. pubmed.gov
  4. OLYMPUS trial (Jelmyto / mitomycin gel for low-grade UTUC), Lancet Oncology 2020. pubmed.gov
  5. Jelmyto FDA label and approval summary. accessdata.fda.gov
  6. ODMIT-C trial (single intravesical mitomycin after RNU), Eur Urol 2011. pubmed.gov
  7. EV-302 trial (enfortumab vedotin + pembrolizumab), NEJM 2024. pubmed.gov
  8. JAVELIN Bladder 100 (maintenance avelumab), NEJM 2020. pubmed.gov
  9. IARC monograph on aristolochic acid. iarc.fr
  10. Bladder Cancer Advocacy Network (BCAN), patient resources including UTUC. bcan.org
  11. SEER Cancer Stat Facts: Urinary Bladder and Upper Tract Urothelial Cancer. seer.cancer.gov
  12. American Cancer Society: Bladder Cancer (shared urothelial background). cancer.org
  13. National Society of Genetic Counselors (find a counselor). nsgc.org
  14. Get Palliative Care: What is palliative care? getpalliativecare.org
  15. ClinicalTrials.gov. clinicaltrials.gov

About this guide. Work through your own situation with your care team. The numbers, vocabulary, and choices here land differently depending on the specifics of your case, and this guide is meant to make those conversations easier, not to stand in for them.

Playing audio...